FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048708312> ?p ?o ?g. }

• W3048708312 abstract "Abstract Background In cluster randomized crossover (CRXO) trials, groups of participants (i.e., clusters) are randomly allocated to receive a sequence of interventions over time (i.e., cluster periods). CRXO trials are becoming more comment when they are feasible, as they require fewer clusters than parallel group cluster randomized trials. However, CRXO trials have not been frequently used in orthopedic fracture trials and represent a novel methodological application within the field. To disseminate the early knowledge gained from our experience initiating two cluster randomized crossover trials, we describe our process for the identification and selection of the orthopedic practices (i.e., clusters) participating in the PREP-IT program and present data to describe their key characteristics. Methods The PREP-IT program comprises two ongoing pragmatic cluster randomized crossover trials (Aqueous-PREP and PREPARE) which compare the effect of iodophor versus chlorhexidine solutions on surgical site infection and unplanned fracture-related reoperations in patients undergoing operative fracture management. We describe the process we used to identify and select orthopedic practices (clusters) for the PREP-IT trials, along with their characteristics. Results We identified 58 potential orthopedic practices for inclusion in the PREP-IT trials. After screening each practice for eligibility, we selected 30 practices for participation and randomized each to a sequence of interventions (15 for Aqueous-PREP and 20 for PREPARE). The majority of orthopedic practices included in the Aqueous-PREP and PREPARE trials were situated in level I trauma centers (100% and 87%, respectively). Orthopedic practices in the Aqueous-PREP trial operatively treated a median of 149 open fracture patients per year, included a median of 11 orthopedic surgeons, and had access to a median of 5 infection preventionists. Orthopedic practices in the PREPARE trial treated a median of 142 open fracture and 1090 closed fracture patients per year, included a median of 7.5 orthopedic surgeons, and had access to a median of 6 infection preventionists. Conclusions The PREP-IT trials provide an example of how to follow the reporting standards for cluster randomized crossover trials by providing a clear definition of the cluster unit, a thorough description of the cluster identification and selection process, and sufficient description of key cluster characteristics. Trial registration Both trials are registered at ClinicalTrials.gov (A-PREP: NCT03385304 December 28, 2017, and PREPARE: NCT03523962 May 14, 2018)." @default.
• W3048708312 created "2020-08-18" @default.
• W3048708312 creator A5007905915 @default.
• W3048708312 creator A5009947652 @default.
• W3048708312 creator A5011288626 @default.
• W3048708312 creator A5012468553 @default.
• W3048708312 creator A5022106962 @default.
• W3048708312 creator A5029801001 @default.
• W3048708312 creator A5031099614 @default.
• W3048708312 creator A5043974518 @default.
• W3048708312 creator A5045540294 @default.
• W3048708312 creator A5048125439 @default.
• W3048708312 creator A5053664457 @default.
• W3048708312 creator A5053960725 @default.
• W3048708312 creator A5056033538 @default.
• W3048708312 creator A5056447624 @default.
• W3048708312 creator A5073437697 @default.
• W3048708312 creator A5073854380 @default.
• W3048708312 creator A5076984868 @default.
• W3048708312 date "2020-08-12" @default.
• W3048708312 modified "2023-10-15" @default.
• W3048708312 title "Cluster identification, selection, and description in cluster randomized crossover trials: the PREP-IT trials" @default.
• W3048708312 cites W2014514659 @default.
• W3048708312 cites W2102330235 @default.
• W3048708312 cites W2115847788 @default.
• W3048708312 cites W2560774895 @default.
• W3048708312 cites W2747813833 @default.
• W3048708312 cites W3014483166 @default.
• W3048708312 cites W4210297421 @default.
• W3048708312 doi "https://doi.org/10.1186/s13063-020-04611-9" @default.
• W3048708312 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7425374" @default.
• W3048708312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32787892" @default.
• W3048708312 hasPublicationYear "2020" @default.
• W3048708312 type Work @default.
• W3048708312 sameAs 3048708312 @default.
• W3048708312 citedByCount "5" @default.
• W3048708312 countsByYear W30487083122020 @default.
• W3048708312 countsByYear W30487083122021 @default.
• W3048708312 countsByYear W30487083122022 @default.
• W3048708312 crossrefType "journal-article" @default.
• W3048708312 hasAuthorship W3048708312A5007905915 @default.
• W3048708312 hasAuthorship W3048708312A5009947652 @default.
• W3048708312 hasAuthorship W3048708312A5011288626 @default.
• W3048708312 hasAuthorship W3048708312A5012468553 @default.
• W3048708312 hasAuthorship W3048708312A5022106962 @default.
• W3048708312 hasAuthorship W3048708312A5029801001 @default.
• W3048708312 hasAuthorship W3048708312A5031099614 @default.
• W3048708312 hasAuthorship W3048708312A5043974518 @default.
• W3048708312 hasAuthorship W3048708312A5045540294 @default.
• W3048708312 hasAuthorship W3048708312A5048125439 @default.
• W3048708312 hasAuthorship W3048708312A5053664457 @default.
• W3048708312 hasAuthorship W3048708312A5053960725 @default.
• W3048708312 hasAuthorship W3048708312A5056033538 @default.
• W3048708312 hasAuthorship W3048708312A5056447624 @default.
• W3048708312 hasAuthorship W3048708312A5073437697 @default.
• W3048708312 hasAuthorship W3048708312A5073854380 @default.
• W3048708312 hasAuthorship W3048708312A5076984868 @default.
• W3048708312 hasBestOaLocation W30487083121 @default.
• W3048708312 hasConcept C126322002 @default.
• W3048708312 hasConcept C141071460 @default.
• W3048708312 hasConcept C142724271 @default.
• W3048708312 hasConcept C159110408 @default.
• W3048708312 hasConcept C164866538 @default.
• W3048708312 hasConcept C168563851 @default.
• W3048708312 hasConcept C176400912 @default.
• W3048708312 hasConcept C1862650 @default.
• W3048708312 hasConcept C199360897 @default.
• W3048708312 hasConcept C204787440 @default.
• W3048708312 hasConcept C27081682 @default.
• W3048708312 hasConcept C27415008 @default.
• W3048708312 hasConcept C41008148 @default.
• W3048708312 hasConcept C535046627 @default.
• W3048708312 hasConcept C68312169 @default.
• W3048708312 hasConcept C71924100 @default.
• W3048708312 hasConcept C87813604 @default.
• W3048708312 hasConceptScore W3048708312C126322002 @default.
• W3048708312 hasConceptScore W3048708312C141071460 @default.
• W3048708312 hasConceptScore W3048708312C142724271 @default.
• W3048708312 hasConceptScore W3048708312C159110408 @default.
• W3048708312 hasConceptScore W3048708312C164866538 @default.
• W3048708312 hasConceptScore W3048708312C168563851 @default.
• W3048708312 hasConceptScore W3048708312C176400912 @default.
• W3048708312 hasConceptScore W3048708312C1862650 @default.
• W3048708312 hasConceptScore W3048708312C199360897 @default.
• W3048708312 hasConceptScore W3048708312C204787440 @default.
• W3048708312 hasConceptScore W3048708312C27081682 @default.
• W3048708312 hasConceptScore W3048708312C27415008 @default.
• W3048708312 hasConceptScore W3048708312C41008148 @default.
• W3048708312 hasConceptScore W3048708312C535046627 @default.
• W3048708312 hasConceptScore W3048708312C68312169 @default.
• W3048708312 hasConceptScore W3048708312C71924100 @default.
• W3048708312 hasConceptScore W3048708312C87813604 @default.
• W3048708312 hasFunder F4320306078 @default.
• W3048708312 hasFunder F4320308927 @default.
• W3048708312 hasFunder F4320319981 @default.
• W3048708312 hasFunder F4320334506 @default.
• W3048708312 hasIssue "1" @default.
• W3048708312 hasLocation W30487083121 @default.
• W3048708312 hasLocation W30487083122 @default.
• W3048708312 hasLocation W30487083123 @default.

• next